Familial hypercholesterolaemia: A model of care for Australasia
Watts, GF
Sullivan, DR
Poplawski, N
van Bockxmeer, F
Hamilton-Craig, I
Clifton, PM
O'Brien, R
Bishop, W
George, P
Barter, PJ
Bates, T
Burnett, JR
Coakley, J
Davidson, P
Emery, J
Martin, A
Farid, W
Freeman, L
Geelhoed, E
Juniper, A
Kidd, A
Kostner, K
Krass, I
Livingston, M
Maxwell, S
O'Leary, P
Owaimrin, A
Redgrave, TG
Reid, N
Southwell, L
Suthers, G
Tonkin, A
Towler, S
Trent, R
Emery, J
Martin, A
Farid, W
Freeman, L
Geelhoed, E
Juniper, A
Kidd, A
Kostner, K
Krass, I
Livingston, M
Maxwell, S
O'Leary, P
Owaimrin, A
Redgrave, TG
Reid, N
Southwell, L
Suthers, G
Tonkin, A
Towler, S
Trent, R
- Publication Type:
- Journal Article
- Citation:
- Atherosclerosis Supplements, 2011, 12 (2), pp. 221 - 263
- Issue Date:
- 2011-10-01
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
 | 2011004261OK.pdf | 1.03 MB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma cholesterol and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but the vast majority remains undetected and those diagnosed with the condition are inadequately treated.To bridge this major gap in coronary prevention the FH Australasia Network (Australian Atherosclerosis Society) has developed a consensus model of care (MoC) for FH. The MoC is based on clinical experience, expert opinion, published evidence and consultations with a wide spectrum of stakeholders, and has been developed for use primarily by specialist centres intending starting a clinical service for FH. This MoC aims to provide a standardised, high-quality and cost-effective system of care that is likely to have the highest impact on patient outcomes.The MoC for FH is presented as a series of recommendations and algorithms focusing on the standards required for the detection, diagnosis, assessment and management of FH in adults and children. The process involved in cascade screening and risk notification, the backbone for detecting new cases of FH, is detailed. Guidance on treatment is based on risk stratifying patients, management of non-cholesterol risk factors, safe and effective use of statins, and a rational approach to follow-up of patients. Clinical and laboratory recommendations are given for genetic testing. An integrative system for providing best clinical care is described.This MoC for FH is not prescriptive and needs to be complemented by good clinical judgment and adjusted for local needs and resources. After initial implementation, the MoC will require critical evaluation, development and appropriate modification. © 2011 Elsevier Ireland Ltd.
Please use this identifier to cite or link to this item: